Keyword: R&D

3DP: Manufacturing the Future of Pharma Today

3DP can offer formulation advantages such as better molecule protection, adjustable powder layers and flexibility in dose loading for adaptive clinical trials.

Vivet Therapeutics

Vivet is harnessing the power of gene therapy to target Wilson disease and other rare genetic disorders as it looks to shake off a tough few years for research and sales in the gene therapy field.

Turnstone Biologics

Turnstone Biologics is hoping to buck a difficult trend in the research world of oncolytic viruses and cancer vaccines by using a combined and systemic approach to create a truly next-generation therapy in immuno-oncology.

Tango Therapeutics

Tango uses CRISPR-enabled synthetic lethality to target cancer, but what really sets it apart is its paradigm-shifting approach that puts patient selection before target identification.

Repare Therapeutics

CRISPR has made it possible for Repare to increase both the scale and precision of the search for drug targets that can induce synthetic lethality in cancer cells.

Relay Therapeutics

Because proteins move constantly inside cells, Relay’s A-list founders and investor Third Rock Ventures think showing motion will reveal new ways to treat diseases. The first step is to go after the many frequently mutated oncogenes the industry is yet to drug.

PsiOxus Therapeutics

PsiOxus thinks it has figured out how to systemically deliver viruses that only replicate in tumor cells. That turned heads at Bristol-Myers Squibb, which struck two deals with PsiOxus last year and provided a launchpad for a pipeline that uses viruses to directly kill cancer cells.

PMV Pharma

PMV Pharma has been trying to tackle cancer by developing small molecules to correct the mutated p53 protein without negatively affecting normal versions of it.